Medisafe Demonstrates Multi-Month Adherence Lift in Study by IMS Health

Results show Medisafe users with hypertension, hyperlipidemia and diabetes have significantly higher adherence than control group

Oct 29, 2015, 16:00 ET from Medisafe

BOSTON, Oct. 29, 2015 /PRNewswire/ -- Medisafe, the leading mHealth platform for medication management with over 2.3 million users, announced today the results of a study conducted by IMS Health that showed that Medisafe users taking cholesterol, hypertension and diabetes medication had 10.7%, 5.4%, and 7.7% higher adherence respectively than a control group of non-users over a multi-month period.

"When patients don't follow their prescribed medication regimen, hypertension, hyperlipidemia and diabetes often lead to more serious illness, most notably cardiovascular disease, the leading cause of death in the U.S., which accounts for 17% of our nation's health costs," said Jon Michaeli, Medisafe's EVP Marketing and Business Development. "Persistence is critical with these chronic conditions – and particularly difficult to achieve with any behavior change – so we are thrilled to share these positive results."

Study Rationale

Medisafe's study focused on these three chronic conditions, due to:

  • Their prevalence in the U.S. (and global) populations: Today, 73.5 million adults (31.7%) in the U.S. have high low-density lipoprotein (LDL) or "bad" cholesterol, 77.9 million have high blood pressure and 29 million have diabetes.
  • Their connection to major health complications (e.g. heart attack, stroke, kidney disease) when undertreated: Prior research shows a continuous decrease in hospitalization risk and total healthcare cost (i.e. medical plus drug costs) when medication adherence rises across the spectrum.
  • The high cost associated with non-adherence: In 2010, the total direct national cost of non-adherence amongst adults for all three conditions was estimated to be $105.8 billion.
  • Other key drivers and incentives to reduce healthcare costs: Medications for all three conditions are included in the Centers for Medicare & Medicaid Services' (CMS) Quality Measures for Medicare Part D.

"Our founding vision was to go way beyond reminding people to take their medications; we are starting to realize our goal of creating measurable benefits to both patients and the healthcare industry, with many more proof points to come in 2016 and beyond," said Omri Shor, Medisafe CEO.

"Even before the conclusion of this study, IMS Health's AppScript team recognized Medisafe as the highest-rated medication management app in terms of AppScript Score as seen in our recent IMS Institute for Healthcare Informatics report, Patient Adoption of mHealth," said Brian Clancy, Senior Product Manager, IMS Health AppScript. "When our team examined the data of Medisafe users versus non-Medisafe users, it became clear that the application was making a significant improvement in medication adherence."

Full Results

Patient Cohort

Timeframe

Test

Control

Absolute Lift

Relative Lift

Hyperlipidemia (n=150) 

6 Months

65.3%

54.7%

+10.7%*

+19.5%

Hypertension (n=406) 

6 Months

69.7%

64.3%

+5.4%*

+8.4%

Diabetes (n=143) 

3 Months

84.6%

76.9%

+7.7%*

+10.0%

* Difference between test and control is significant at the 95% level 

"As a diabetic and a doctor, I'm well aware of the short-term discomfort of missing medications as well as the long-term impact from poor blood glucose control that often leads to serious – and costly – complications later in life," said Dr. Daniel Mosby, a Medisafe user and junior doctor from the United Kingdom. "Personally, achieving 100% adherence with Medisafe has made an immense difference in my immediate well-being and is an investment in my long-term health. Professionally, these latest data points only reinforce my belief that the Medisafe application is a great option for healthcare providers who need to assist their patient population with adherence."

The Medisafe / IMS study bolsters the results of an internal study Medisafe reported last month showing a segment of its Stage 1 and 2 hypertension users – those using a connected blood pressure cuff – decreased their systolic blood pressure by an average of 19.3 mmHg. Results of all Medisafe research studies can be found at www.medisafe.com/research.

About Medisafe

Medisafe is the leading cloud-synced mHealth platform that helps patients stay on top of all their medications. More than just a pill organizer, Medisafe makes it easy to adhere to the most complicated medication schedules, enables care collaboration between a patient, their loved ones and physicians, and delivers content and services personalized to specific conditions and situations. Medisafe's over 2.3 million users have recorded over 230 million successful medication doses on their iOS and Android smartphones and tablets, leading to 90,000 user reviews that average 4.5 out of 5 stars in the iTunes and Google Play app stores. 

About IMS Health

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company's 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.

About AppScript

AppScript™ is the leading discovery and distribution platform for mobile health technologies. The AppScript team has curated and characterized thousands of mobile healthcare apps, hundreds of connected devices, and millions of pieces of educational content by condition and stage of the patient journey. Each mobile health technology is assessed using the company's proprietary IMS Health AppScript Score, which ranks apps and devices based on six primary metrics: functionality, professional reviews, patient reviews, endorsements, developer trust ratings and clinical ratings. AppScript enables any healthcare professional to securely prescribe, track and reconcile mobile health content prescribed to patients and caregivers. Learn more at http://www.appscript.net.

Contact:

Ariela Weinberger
ariela.weinberger@venture1st.com
610-716-2978

Photo - http://photos.prnewswire.com/prnh/20151029/281876-INFO

Logo - http://photos.prnewswire.com/prnh/20150817/258916LOGO

SOURCE Medisafe



RELATED LINKS

http://www.medisafe.com